KRAS and head and neck squamous cell carcinoma: Interestingly, Weidhaas et al. recently performed a secondary analysis of a randomized phase III HNSCC trial and found that patients with an oncogenic germline KRAS variant (a let-7 microRNA-binding site polymorphism in the 3’ untranslated region of KRAS) have significantly better clinical outcomes with cetuximab (EGFR monoclonal antibody) addition to radiotherapy plus cisplatin regimen58.